Cost-effectiveness analysis and safety of erythromycin 4% gel and 4% chlorhexidine scrub for pitted keratolysis treatment

J Dermatolog Treat. 2019 Sep;30(6):627-629. doi: 10.1080/09546634.2018.1543846. Epub 2018 Dec 11.

Abstract

Background: Studies of Pitted keratolysis (PK) treatment are limited. Objectives: To study cost-effectiveness and to compare the safety of 4% chlorhexidine scrub with 4% erythromycin gel, for PK infections. Materials and methods: This cohort study was conducted on naval rating cadets with a clinical diagnosis of PK at Chumpol Naval Rating School, Thailand in 2016. Participants were randomly treated with either 4% erythromycin gel or 4% chlorhexidine scrub for 4 weeks. The clinical examinations were evaluated at the baseline and at 1 and 2 months after treatment. A decision-tree model was used to evaluate the costs, resource utilization and outcomes as quality-adjusted life-years (QALYs). Results: Of 344 naval rating cadets, 125 (36.3%) were diagnosed with PK. Sixty-four were treated with erythromycin. Approximately 80% of participants had complete resolution Foot odor were significantly improved at 2 months (p < .001) for both groups. No adverse effects were reported. Total cost for 4 weeks' treatment with the erythromycin gel and chlorhexidine scrub was US$77.34, US$51.9, respectively. Chlorhexidine treatment and erythromycin gel had 0.1526 and 0.1425 QALYs, respectively. Conclusions: treatment of PK with either 4% chlorhexidine scrub or 4% erythromycin gel had similar outcomes. However, using chlorhexidine scrub was more cost-effective.

Keywords: Pitted keratolysis; chlorhexidine scrub; cost-effectiveness analysis; erythromycin gel; safety; treatment.

MeSH terms

  • Chlorhexidine / adverse effects
  • Chlorhexidine / pharmacokinetics
  • Chlorhexidine / therapeutic use*
  • Cohort Studies
  • Cost-Benefit Analysis*
  • Drug Administration Schedule
  • Erythromycin / adverse effects
  • Erythromycin / pharmacokinetics
  • Erythromycin / therapeutic use*
  • Gels / chemistry
  • Half-Life
  • Humans
  • Keratosis / drug therapy*
  • Keratosis / economics

Substances

  • Gels
  • Erythromycin
  • Chlorhexidine